Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 18 recruiting now early-phase tilt

Lymphedema: early-phase trial registry

18 of 35 indexed Lymphedema trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #435 of 28,707 conditions by registered trial count.

35 US clinical trials · 18 currently recruiting · #435 of 28,707 conditions by registered trial count

Lymphedema: 35 US clinical trials tracked, 18 recruiting.

Lymphedema is the subject of 35 registered US clinical trials on ClinicalTrials.gov, 18 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.

Enrollment posture brief

Registry condition lymphedema

OPEN 18 | RECR 51% | LATE 2 | EARLY 7 | RANK #435 | SPON 4

Nearest open-share peer: Suicide, Attempted (51% recruiting · 37 trials)

Cannabis Use Disorder71.4%Cirrhosis, Liver60%Lymphedema (this)51%Carcinoma, Renal Cell17.1%Advanced Lymphoma8.6%
Open-enrollment share among volume-matched conditions near Lymphedema

Lymphedema lists 18 open slots (51% of 35 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lymphedema on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lymphedema is recruiting above its size-band peers.

    18 of 35 indexed trials (51.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Lymphedema trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 4 of 35 trials (11.4%). 25 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lymphedema enrolment sits around 101 participants.

    Median target enrolment is 101 among the 35 trials that report a genuine target (sentinel values excluded). 16 of those (45.7%) plan for fewer than 100 participants.

  4. Lymphedema splits between interventional and observational designs.

    24 interventional and 11 observational studies make up this index (68.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 26Phase 31Phase 41

Open and recent trials

35 total, page 1 of 1

RECRUITING 300,000 participants

A Real-World Registry of Chronic Wounds and Ulcers

U.S. Wound Registry

NCT02280733

RECRUITING 10,000 participants

Prospective Screening for Breast Cancer-related Lymphedema

Massachusetts General Hospital

NCT01521741

RECRUITING 1,250 participants

Lymphedema Surveillance Study

Memorial Sloan Kettering Cancer Center

NCT02743858

RECRUITING 600 participants

A Study Comparing Quality of Life in Patients With Lymphedema Who Undergo Surgical Treatment Versus Non-Surgical Management

Memorial Sloan Kettering Cancer Center

NCT03248310

RECRUITING 500 participants

Vascular Lab Resource (VLR) Biorepository

The Cleveland Clinic

NCT05628948

RECRUITING 455 participants

A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons

MMI (Medical Microinstruments, Inc.)

NCT06725030

RECRUITING NA 300 participants

Comparing Two Ways to Manage Head and Neck Lymphedema

Abramson Cancer Center at Penn Medicine

NCT05182229

RECRUITING Phase 2 295 participants

Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

M.D. Anderson Cancer Center

NCT06494111

RECRUITING Phase 3 285 participants

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT06144164

RECRUITING Phase 2 250 participants

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

M.D. Anderson Cancer Center

NCT06912763

RECRUITING Early Phase 1 110 participants

Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema

Advanced Reconstructive Surgery Alliance

NCT07012642

RECRUITING NA 100 participants

Clinical Study to Evaluate the Effectiveness and Health Economics of a Novel Portable Non-Pneumatic Active Compression Device (NPCD) for Lymphedema/Phlebolymphedema

Koya Medical

NCT06418282

RECRUITING NA 80 participants

LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy

Stanford University

NCT05366699

RECRUITING NA 72 participants

Pedal Pump and Leg Lymphedema

Rowan University

NCT06235463

RECRUITING NA 60 participants

Surgical Evaluation for Upper Extremity Lymphedema (BioBridge)

Fibralign Corporation

NCT05695924

RECRUITING NA 60 participants

LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)

Fibralign Corporation

NCT04606030

RECRUITING Phase 2 50 participants

Lymphedema Prevention Through Immediate Lymphatic Reconstruction (LILY) Trial.

M.D. Anderson Cancer Center

NCT06989099

RECRUITING NA 20 participants

A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients With Breast Cancer Related Lymphedema (BCRL) After Lymphatic Surgery

Koya Medical

NCT04888975

ACTIVE NOT RECRUITING NA 260 participants

PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema

M.D. Anderson Cancer Center

NCT05056207

ACTIVE NOT RECRUITING NA 224 participants

Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer

GOG Foundation

NCT01649089

ACTIVE NOT RECRUITING 166 participants

Screening For BCRL In Targeted Therapy For Breast Cancer

Massachusetts General Hospital

NCT05142800

ACTIVE NOT RECRUITING 101 participants

Lymphedema Specific PROs for Risk Assessment, Prevention and Early Detection

University of Miami

NCT05929001

ACTIVE NOT RECRUITING NA 76 participants

Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study

Ohio State University Comprehensive Cancer Center

NCT06305884

ACTIVE NOT RECRUITING NA 67 participants

Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection

OrthoCarolina Research Institute

NCT00984269

COMPLETED NA 236 participants

A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema

Tactile Medical

NCT04797390

COMPLETED 145 participants

The Impact of Lymphedema on Breast Cancer Survivors

University of California, San Francisco

NCT00769821

COMPLETED NA 120 participants

Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow)

NYU Langone Health

NCT02462226

COMPLETED 80 participants

Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis

Vanderbilt-Ingram Cancer Center

NCT02676752

COMPLETED NA 75 participants

Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status

Stanford University

NCT00383500

COMPLETED Phase 2 54 participants

Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)

Eiger BioPharmaceuticals

NCT02700529

COMPLETED Phase 4 50 participants

Low Level Laser Treatment and Breast Cancer Related Lymphedema

Vanderbilt University

NCT00852930

COMPLETED 30 participants

Lymphedema Sensor Technology Development Study

Northwestern University

NCT06778837

COMPLETED Phase 2 10 participants

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Kathy Miller

NCT00827372

COMPLETED NA 9 participants

Intraoperative Evaluation of Axillary Lymphatics

University of Wisconsin, Madison

NCT05094102

COMPLETED Phase 2 2 participants

Pycnogenol for the Treatment of Lymphedema

University of Wisconsin, Madison

NCT00214032

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 6
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Lymphedema records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Vascularized Lymph Node Transfer (VLNT) Procedure
2 trials
BioBridge® Collagen Matrix Device
2 trials
Pentoxifylline Drug
2 trials
Questionnaire Administration Other
2 trials
Shear Wave Elastography Procedure
1 trials
Medical Examination Procedure
1 trials
OnLume Imaging System Device
1 trials
Class 1 compression garment Device
1 trials

US sites by state

Facility locations filed on Lymphedema trials. A trial with sites in several states counts in each.

California 8 trials
Texas 7 trials
New York 6 trials
New Jersey 5 trials
Ohio 4 trials
Tennessee 3 trials
Illinois 3 trials
Florida 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lymphedema page

35 registered trials, 18 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphedema condition card totals 35 registered trials; most-linked intervention Vascularized Lymph Node Transfer (VLNT); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.